Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.
Open Access
- 1 November 1993
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 92 (5) , 2152-2159
- https://doi.org/10.1172/jci116816
Abstract
Neoplastic diseases are frequently associated with metabolic changes collectively known as cancer cachexia. The presence of cachexia complicates therapeutic intervention and is an important cause of death in cancer patients. At present there is no effective treatment for cachexia. Recently, the involvement of interleukin-6 (IL-6) in the wasting of colon-26 adenocarcinoma-bearing mice was demonstrated. The research presented here establishes an anticachectic role for the experimental drug suramin, since it partially blocks (up to 60%) the catabolic effects associated with the growth of this tumor in vivo. Suramin prevents the binding of IL-6 to its cell surface receptor subunits, as demonstrated by radioreceptor binding assay and affinity crosslinking experiments. Furthermore, the uptake of radioactive IL-6 by the liver is significantly reduced in suramin-treated mice. On the other hand, the drug is approximately 10-fold less potent in inhibiting the binding of tumor necrosis factor-alpha to indicator cell line in vitro and fails to block liver uptake of this cytokine in vivo. Collectively, these results suggest that suramin inhibits cancer-associated wasting, in part by interfering with the binding of IL-6 to its receptor. Whether suramin inhibits the action of other factors/cytokines that may also participate in colon-26-mediated cachexia is not yet known.Keywords
This publication has 35 references indexed in Scilit:
- Effects of Suramin on In Vitro Growth of Fresh Human TumorsJNCI Journal of the National Cancer Institute, 1992
- Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitroImmunology Today, 1991
- Biological and clinical aspects of interleukin 6Immunology Today, 1990
- Molecular cloning and expression of an IL-6 signal transducer, gp130Cell, 1990
- Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.The Journal of Experimental Medicine, 1988
- Novel Interleukin-2 Receptor Subunit Detected by Cross-Linking Under High-Affinity ConditionsScience, 1986
- Reduced Plasma Lipoprotein Lipase Activity in Patients with Malignancy-Associated Weight LossHormone and Metabolic Research, 1986
- Detection and characterization of high affinity plasma membrane receptors for human interleukin 1.The Journal of Experimental Medicine, 1985
- Prognostic effect of weight loss prior tochemotherapy in cancer patientsThe American Journal of Medicine, 1980
- Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor virusesCancer Letters, 1979